Dr. Erkut Borazanci, MD, Joins Vivacitas Oncology’s Pancreatic Medical Advisory Board
Vivacitas proudly announces that Dr. Erkut Borazanci, MD, has joined its Pancreatic Medical Advisory Board.
Vivacitas Oncology to present AR-67 at the Biotech Showcase Investor Conference
Vivacitas announces that its CEO, Mark Suseck, will present at the 2022 Biotech Showcase Conference, an investors event focused on biotechnology innovation that will be held virtually next January 10-12 and 17-19
Vivacitas Oncology welcomes Dr. Jai Grewal, MD, and expands its Neuro-Oncology Advisory Board
Vivacitas Oncology, Inc. is pleased to announce that Dr. Jai Grewal, MD, has agreed to become a new member of their distinguished Neuro-Oncology Advisory Board. Dr. Grewal will be joining Dr. Andrew Lassman, MD, MS, FAAN in the company’s Scientific Advisory Board.
Vivacitas Oncology Presents its New Neuro-Oncology Advisor, Dr. Andrew Lassman MD, MS, FAAN
WALNUT CREEK, CALIFORNIA, US, December 15, 2021 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, is pleased to announce the addition of Dr. Andrew Lassman to their Scientific Advisory Board. Dr. Andrew Lassman With over 20 years of experience in translational neuro-oncology research, Dr. Lassman is board […]